Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Ling

Showing results (131-140 of 164) with videos related to

Pageof 17
Sort By:
Journal of Addiction Medicine|July 6, 2016
Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use DisorderLarissa J Mooney, Maureen P Hillhouse, Christie Thomas, et al.
Addiction (Abingdon, England)|August 22, 2013
Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trialYih-Ing Hser, Andrew J Saxon, David Huang, et al.
Journal of Addiction Medicine|March 19, 2020
Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational StudyWalter Ling, Vijay R Nadipelli, Arnie P Aldridge, et al.
Lancet (London, England)|February 23, 2019
Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialBarbara R Haight, Susan M Learned, Celine M Laffont, et al.
Journal of the American Pharmacists Association : Japha|February 26, 2005
Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/ naloxone to patients with opioid dependenceDennis W Raisch, Paul J Fudala, Andrew J Saxon, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|July 2, 2004
Structural abnormalities in the brains of human subjects who use methamphetaminePaul M Thompson, Kiralee M Hayashi, Sara L Simon, et al.
Journal of Studies on Alcohol and Drugs|June 7, 2013
Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START)Jennifer S Potter, Elise N Marino, Maureen P Hillhouse, et al.
The American Journal of Psychiatry|August 2, 2013
DSM-5 criteria for substance use disorders: recommendations and rationaleDeborah S Hasin, Charles P O'Brien, Marc Auriacombe, et al.
Addiction (Abingdon, England)|December 1, 2011
A randomized controlled trial of a brief intervention for illicit drugs linked to the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) in clients recruited from primary health-care settings in four countriesRachel Humeniuk, Robert Ali, Thomas Babor, et al.
Addiction (Abingdon, England)|May 15, 2014
Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorderWalter Ling, Linda Chang, Maureen Hillhouse, et al.
Pageof 17

Showing results (131-140 of 164) with videos related to

Sort By:
Pageof 17
Journal of Addiction Medicine|July 6, 2016
Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use DisorderLarissa J Mooney, Maureen P Hillhouse, Christie Thomas, et al.
Addiction (Abingdon, England)|August 22, 2013
Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trialYih-Ing Hser, Andrew J Saxon, David Huang, et al.
Journal of Addiction Medicine|March 19, 2020
Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational StudyWalter Ling, Vijay R Nadipelli, Arnie P Aldridge, et al.
Lancet (London, England)|February 23, 2019
Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialBarbara R Haight, Susan M Learned, Celine M Laffont, et al.
Journal of the American Pharmacists Association : Japha|February 26, 2005
Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/ naloxone to patients with opioid dependenceDennis W Raisch, Paul J Fudala, Andrew J Saxon, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|July 2, 2004
Structural abnormalities in the brains of human subjects who use methamphetaminePaul M Thompson, Kiralee M Hayashi, Sara L Simon, et al.
Journal of Studies on Alcohol and Drugs|June 7, 2013
Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START)Jennifer S Potter, Elise N Marino, Maureen P Hillhouse, et al.
The American Journal of Psychiatry|August 2, 2013
DSM-5 criteria for substance use disorders: recommendations and rationaleDeborah S Hasin, Charles P O'Brien, Marc Auriacombe, et al.
Addiction (Abingdon, England)|December 1, 2011
A randomized controlled trial of a brief intervention for illicit drugs linked to the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) in clients recruited from primary health-care settings in four countriesRachel Humeniuk, Robert Ali, Thomas Babor, et al.
Addiction (Abingdon, England)|May 15, 2014
Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorderWalter Ling, Linda Chang, Maureen Hillhouse, et al.
Pageof 17